IceCure Medical (NASDAQ:ICCM) Issues Quarterly Earnings Results, Misses Expectations By $0.03 EPS

IceCure Medical (NASDAQ:ICCM) released its quarterly earnings results on Tuesday. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by ($0.03), Zacks reports. IceCure Medical had a negative return on equity of 221.04% and a negative net margin of 445.61%.The firm had revenue of $0.91 million for the quarter, compared to analysts’ expectations of $1.34 million.

Here are the key takeaways from IceCure Medical’s conference call:

• IceCure reported Q1 2026 revenue growth of 26% year over year, with North America up 84% and U.S. sales up 31%, driven by a new system placement and higher disposable probe usage.
• The company said U.S. commercial momentum accelerated after FDA clearance for low-risk early breast cancer, with active accounts rising to 19 from 13 pre-clearance, and it expects further growth in the second quarter.
• Management described strong physician and hospital interest in ProSense at major conferences, saying qualified leads are moving through purchasing processes and could convert into system sales and installations over the coming quarters.
• IceCure is expanding its U.S. sales team and advancing the ChoICE post-market study, which will include 30 hybrid clinical/commercial sites and is intended to support adoption, generate additional data, and help reimbursement efforts.
• Reimbursement remains a work in progress: the company plans to submit the CPT 1 code application in June, expects a response in 2027, and believes it could become effective in January 2028, while also pursuing transitional pass-through payment.

IceCure Medical Trading Down 2.9%

ICCM stock traded down $0.01 during mid-day trading on Wednesday, hitting $0.23. 306,590 shares of the company were exchanged, compared to its average volume of 454,172. The company has a market capitalization of $18.91 million, a PE ratio of -0.97 and a beta of 0.47. IceCure Medical has a twelve month low of $0.22 and a twelve month high of $1.40. The firm has a fifty day simple moving average of $0.43 and a 200 day simple moving average of $0.58.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in IceCure Medical stock. Jane Street Group LLC acquired a new position in shares of IceCure Medical Ltd. (NASDAQ:ICCM) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 109,638 shares of the company’s stock, valued at approximately $67,000. Jane Street Group LLC owned approximately 0.16% of IceCure Medical at the end of the most recent reporting period. Institutional investors and hedge funds own 0.62% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on ICCM shares. Wall Street Zen raised shares of IceCure Medical from a “sell” rating to a “hold” rating in a research note on Saturday, February 7th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of IceCure Medical in a research note on Tuesday, April 21st. Finally, Alliance Global Partners started coverage on shares of IceCure Medical in a research note on Monday, May 4th. They set a “buy” rating on the stock. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, IceCure Medical has an average rating of “Hold” and a consensus target price of $2.64.

IceCure Medical Company Profile

IceCure Medical Ltd. (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.

Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017.